Exelixis Initiates Trial In Patients With Non-Small Cell Lung Cancer

Armen Hareyan's picture
Advertisement

Exelixis has initiated a phase 1/2 trial of XL184 in patients with non-small cell lung cancer (NSCLC) who have had progressive disease while on a regimen containing erlotinib.

XL184 is a small molecule that simultaneously inhibits the MET, RET and VEGFR receptor tyrosine kinases. In the initial phase 1 part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the phase 2 part of the study is overall response rate. Secondary endpoints include progression-free survival, overall survival and pharmacodynamics.

"XL184 is a potent inhibitor of MET, and MET amplification has been shown to play an important role in the development of resistance to EGFR inhibitors in NSCLC," said Michael Morrissey, Ph.D., president of research and development of Exelixis. "Our preclinical data suggest that XL184 effectively inhibits growth of cancer cells that have become resistant to EGFR inhibitors through activation of the MET signaling pathway. XL184 also potently inhibits VEGFR, which is a validated target in the treatment of NSCLC. The compound has shown encouraging anti-tumor activity in an initial phase 1 trial and we are executing a phase 2 clinical development program, and are planning on initiation of a pivotal trial for XL184 in medullary thyroid cancer in 2008."

Advertisement

The phase 1/2 study of XL184 is expected to enroll up to 86 NSCLC patients who have had disease progression while on erlotinib. The phase 1 portion of the study will evaluate dose escalation of XL184 in combination with erlotinib, both administered daily. Patients in the first cohort will receive a dose of XL184 that is below the maximum tolerated dose (MTD) identified in the ongoing phase 1 trial of XL184, in combination with erlotinib. Subsequent cohorts will receive erlotinib in combination with escalating doses of XL184 until the MTD is reached. In the phase 2 portion of the study, patients will be randomized to receive XL184 at the MTD alone or in combination with erlotinib. Additionally, correlative studies will evaluate MET amplification and EGFR mutational status. MET and EGFR signaling activity will be assessed in tumor and surrogate tissue.

Data from an ongoing phase 1 trial of XL184 in patients with advanced malignancies were presented in October 2007 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract #A152). Investigators reported that anti-tumor activity had been observed in a variety of cancers at doses that are not associated with significant toxicity. There were 33 patients available for safety, pharmacokinetic and tumor response analyses as of the June 22, 2007 cutoff; further data were also provided for six additional patients after the cutoff. Of seven patients with medullary thyroid cancer (MTC), three had partial responses (two confirmed and one unconfirmed) as of the date of the AACR-NCI- EORTC Conference. In addition, as of such date, six of the seven patients had tumor shrinkage and one had non-measurable disease. All seven assessable patients with MTC experienced a rapid decrease in plasma levels of calcitonin, a marker frequently elevated in MTC, and six of the seven patients had a decrease in the tumor marker carcinoembryonic antigen. All seven MTC patients remain on study. In addition, one patient with a neuroendocrine tumor has an unconfirmed partial response. In total, 15 patients with various malignancies have had stable disease lasting from 3 - 20 months, including nine patients with stable disease for more than six months.

To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema (hand-foot syndrome), Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg (intermittent dosing schedule), as well as a DLT of Grade 2 mucositis in a patient dosed at 265 mg (daily dosing schedule). Serious adverse events (AEs) considered possibly or probably related to XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary embolism. Dose escalation continues in order to determine a maximum tolerated dose (MTD).

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement